PathoQuest

16 articles about PathoQuest

• Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods

  9/6/2023

  Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods.

• Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market

  3/21/2023

  Oxford Nanopore Technologies plc and PathoQuest announce the agreement of a MOU for a collaboration to commercialise a transformational Integration Site Analysis test to better meet the evolving needs of the biopharmaceutical industry and the advancement of biological therapeutics.

• PathoQuest Receives GMP Certification for Its NGS-based Quality Control Testing Services of Biological Drugs

  11/24/2021

  PathoQuest today announced that it has obtained a Good Manufacturing Practices (GMP) certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM).

• Charles River and PathoQuest Strengthen Strategic Partnership

  11/12/2020

  PathoQuest establishes U.S. subsidiary with state-of-the-art biologics genomic testing laboratory in Wayne, PA to expand its next-generation sequencing capabilities

• PathoQuest Secures 8 Million Euros in New Financing

  9/5/2019

  PathoQuest announces the closing of an 8M euros financing series.

• PathoQuest Names Dr. Christiane Honisch to Board of Directors

  9/25/2018

  PathoQuest today announced the appointment of Christiane Honisch, Ph.D. as an independent member of the Company’s Board of Directors.

• PathoQuest Announces New Appointments to Executive Leadership Team

  7/10/2018

  Company adds experienced executives to support the continued growth of Biologics Genomic Service and Clinical Diagnostics businesses which utilize PathoQuest’s proprietary Next-Generation Sequencing (NGS) based testing solution.

• PathoQuest Announces Enrollment of First Patient in IDENTIFY, a Prospective Clinical Study Assessing the Medico-Economic Benefit of iDTECT™ Blood for the Diagnosis of Bloodstream Infection in Immunocompromised Patients

  5/22/2018

  PathoQuest, a genomic expert for biologics testing and a leader in improving pathogen identification in clinical biological samples, today announced the initiation and enrollment of the first patient in a medico-economic study testing the company’s metagenomic iDTECT™ Blood test.

• Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership

  4/9/2018

  Charles River will provide clients access to PathoQuest’s NGS-based testing solutions

• PathoQuest and Mayo Clinic Enter Into an Agreement to Conduct Study of iDTECT Blood in Patients With Febrile Neutropenia

  12/14/2017

  PathoQuest announced that it will conduct research with Mayo Clinic to study the company’s proprietary iDTECT Blood test.

• PathoQuest Announces Formation of Scientific Advisory Board

  11/20/2017

  Members of the Scientific Advisory Board are recognized infectious diseases, microbiology and next-generation sequencing experts.

• PathoQuest Collaborating With Memorial Sloan Kettering Cancer Center to Study iDTECT Blood In Patients With Febrile Neutropenia

  11/7/2017

  iDTECT Blood is the only CE-IVD NGS-based test which offers a culture-free, agnostic metagenomic approach to improving the breadth of pathogen detection. 

• PathoQuest Release: Proof-Of-Concept Study Published In Clinical Microbiology And Infection Reports The Benefit Of Pathoquest NGS-Based Metagenomics Test To Identify Clinically-Relevant Pathogens In Immunocompromised Patients Suspected Of Infection

  2/22/2017

• PathoQuestAchieves CE Mark For The iDTECT Blood Test

  10/27/2016

• PathoQuest Announces Appointments To Executive Leadership Team

  10/18/2016

• PathoQuest Announces Partnership With Charles River

  9/29/2016